The Scientist

» cancer, evolution and disease/medicine

Most Recent

A transposon underlies this classic story of evolutionary adaptation.

1 Comment

Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.

1 Comment

image: Contributors


By | June 1, 2016

Meet some of the people featured in the June 2016 issue of The Scientist.


image: Screening  with CRISPR

Screening with CRISPR

By | June 1, 2016

Ever-improving CRISPR-based tools are already ripe for large-scale genetic screens.

1 Comment

image: Start Making Sense

Start Making Sense

By | June 1, 2016

Scientific progress is only achieved when humans' innate sense of understanding is validated by objective reality.


Member, Department of Immunology, St. Jude Children’s Research Hospital. Age: 43


image: Toward Targeted Therapies for Autoimmune Disorders

Toward Targeted Therapies for Autoimmune Disorders

By | June 1, 2016

Training the immune system to cease fire on native tissues could improve outcomes for autoimmune patients, but clinical progress has been slow.


Exposing male rats to nonionizing radiation increased the animals’ risk of brain and heart tumors in a study, but the findings are far from conclusive.


Caltech’s Frances Arnold is honored for her work on directed evolution.

1 Comment

image: FDA Approves Bladder Cancer Immunotherapy

FDA Approves Bladder Cancer Immunotherapy

By | May 23, 2016

The US Food and Drug Administration greenlights Roche’s Tecentriq, which blocks a protein that obstructs the immune system’s ability to fight cancer.


Popular Now

  1. Genetic Test Solves Royal Mystery
    Notebook Genetic Test Solves Royal Mystery

    Genetic analyses lay to rest conspiracy theories about death of Belgian King Albert I, who lost his life in a rock climbing accident more than 80 years ago.

  2. Investigation Finds Pathologist Guilty of Systemic Misconduct
  3. Bacteria and Humans Have Been Swapping DNA for Millennia
  4. Curious George
    The Scientist Curious George

    George Church has consistently positioned himself at genomics’ leading edge.